EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

/PRNewswire/ -- EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which...

Related Keywords

Dallas ,Texas ,United States ,University Of Texas ,Prnewswire Epicentrx ,David Sher ,Stephen Sonis ,Faculty Of The Dana Farber Cancer Institute ,University Of Texas Southwestern ,International Journal Of Radiation Oncology ,International Journal ,Radiation Oncology ,Texas Southwestern ,Harvard Professor ,Oral Medicine ,Distinguished Faculty ,Dana Farber Cancer Institute ,Epicentrx ,Nc ,